Health state utility values: A description of their development and application for rheumatic diseases

Arthritis Care and Research

Volumn 59, Issue 7, 2008, Pages 1018-1026

  Bansback, Nick ^a,b   Harrison, Mark ^c   Brazier, John ^b   Davies, Linda ^c   Kopec, Jacek ^d   Marra, Carlo ^d   Symmons, Deborah ^c   Anis, Aslam ^d  

^a CENTRE FOR HEALTH EVALUATION AND OUTCOME SCIENCES   (Canada)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYLOSING SPONDYLITIS; CLINICAL RESEARCH; COST UTILITY ANALYSIS; HEALTH STATE UTILITY VALUE; HEALTH STATUS; HUMAN; NON INVASIVE MEASUREMENT; OSTEOARTHRITIS; OSTEOPOROSIS; PSORIATIC ARTHRITIS; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS;

ACTIVITIES OF DAILY LIVING; HUMANS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RHEUMATIC DISEASES; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE;

EID: 47249101724     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23813     Document Type: Review

References (74)

1. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University; 1996.
2. Tan MC, Regier DA, Esdaile JM, Lynd LD, Anis AH, Marra CA. Health economic evaluation: a primer for the practicing rheumatologist. Arthritis Rheum 2006;55:648-56.
3. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986;5:1-30.
4. Bakker C, van der Linden S. Health related utility measurement: an introduction. J Rheumatol 1995;22:1197-9.
5. Reinhardt UE, Hussey PS, Anderson GF. US health care spending in an international context. Health Aff (Millwood) 2004;23:10-25.
6. Brazier J, Deverill M, Green C, Harper R, Booth A. A review of the use of health status measures in economic evaluation. Health Technol Assess 1999;3:i-iv, 1-164.
7. Center on the Evaluation of Value & Risk in Health. The Cost-Effectiveness Analysis Registry (CEA). Boston: Tufts-New England Medical Center, ICRHPS; 2007. URL: http://www.tufts-nemc.org/cearegistry/.
8. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583-637.
9. Neumann PJ, Brauer C. Measures and strategies for obtaining health benefit values for regulatory analysis. In: Miller W, Robinson LA, Lawrence RS, editors. Valuing health for regulatory cost-effectiveness analysis. Washington (DC): National Academies; 2006. p. 364.
10. National Institute for Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NICE; 2004.
11. Maetzel A, Tugwell P, Boers M, Guillemin F, Coyle D, Drummond M, et al. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol 2003;30:891-6.
12. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada. 3rd ed. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2006.
13. Kirkwood BR. Essentials of medical statistics. Oxford: Blackwell Scientific; 1988.
14. Brazier JE, Ratcliffe J, Salomon J, Tsuchiya A. Measuring and valuing health benefits for economic evaluation. Oxford: Oxford University; 2007.
15. Suarez-Almazor ME, Conner-Spady B. Rating of arthritis health states by patients, physicians, and the general public: implications for cost-utility analyses. J Rheumatol 2001;28:648-56.
16. Gabriel SE, Kneeland TS, Melton LJ III, Moncur MM, Ettinger B, Tosteson AN. Health-related quality of life in economic evaluations for osteoporosis: whose values should we use? Med Decis Making 1999;19:141-8.
17. Rashidi AA, Anis AH, Marra CA. Do visual analogue scale (VAS) derived standard gamble (SG) utilities agree with Health Utilities Index utilities? A comparison of patient and community preferences for health status in rheumatoid arthritis patients. Health Qual Life Outcomes 2006;4:25.
18. Souchek J, Byrne MM, Kelly PA, O'Malley K, Richardson M, Pak C, et al. Valuation of arthritis health states across ethnic groups and between patients and community members. Med Care 2005;43:921-8.
19. Sprangers MA, Schwartz CE. Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med 1999;48:1507-15.
20. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK general population survey. York (UK): University of York; 1995.
21. Furlong WJ, Feeny DH, Torrance GW, Barr RD. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Hamilton (ON): McMaster University; 2001.
22. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92.
23. Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Serv Res 1988;23:203-35.
24. Sintonen H. An approach to measuring and valuing health states. Soc Sci Med [Med Econ] 1981;15:55-65.
25. Rosser R. A health index and output measure. In: Walker SR, Rosser RM, editors. Quality of life: assessment and application Lancaster: MTP Press; 1988.
26. Chiou CF, Weisman M, Sherbourne CD, Reyes C, Dylan M, Ofman J, et al. Measuring preference weights for American College of Rheumatology response criteria for patients with rheumatoid arthritis. J Rheumatol 2005;32:2326-9.
27. Chiou CF, Suarez-Almazor ME, Sherbourne CD, Chang CH, Reyes C, Dylan M, et al. Development and validation of a preference weight multiattribute health outcome measure for rheumatoid arthritis. J Rheumatol 2006;33:2409-11.
28. Patrick DL, Erickson P. Health status and health policy: quality of life in health care evaluation and resource allocation. New York: Oxford University; 1993.
29. Robinson A, Loomes G, Jones-Lee M. Visual analog scales, standard gambles, and relative risk aversion. Med Decis Making 2001;21:17-27.
30. Verhoeven AC, Bibo JC, Boers M, Engel GL, van der Linden S, the COBRA Trial Group, and Combinatietherapie Bij Reumatoide Artritis. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. Br J Rheumatol 1998;37:1102-9.
31. Peeters HR, Jongen-Lavrencic M, Bakker CH, Vreugdenhil G, Breedveld FC, Swaak AJ. Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease: utility measures correlate strongly with disease activity measures. Rheumatol Int 1999;18:201-6.
32. Rutten-van Molken MP, Bakker CH, van Doorslaer EK, van der Linden S. Methodological issues of patient utility measurement: experience from two clinical trials. Med Care 1995;33:922-37.
33. Salaffi F, Stancati A, Carotti M. Responsiveness of health status measures and utility-based methods in patients with rheumatoid arthritis. Clin Rheumatol 2002;21:478-87.
34. Tijhuis GJ, Jansen SJ, Stiggelbout AM, Zwinderman AH, Hazes JM, Vlieland TP. Value of the time trade off method for measuring utilities in patients with rheumatoid arthritis. Ann Rheum Dis 2000;59:892-7.
35. Byrne MM, O'Malley K, Suarez-Almazor ME. Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis. Med Decis Making 2005;25:655-66.
36. Moore AD, Clarke AE, Danoff DS, Joseph L, Belisle P, Neville C, et al. Can health utility measures be used in lupus research? A comparative validation and reliability study of 4 utility indices. J Rheumatol 1999;26:1285-90.
37. Kopec JA, Willison KD. A comparative review of four preference-weighted measures of health-related quality of life. J Clin Epidemiol 2003;56:317-25.
38. Swain L, Catlin G, Beaudet MP. The National Population Health Survey: its longitudinal nature. Health Rep 1999;10:69-82.
39. Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG. Report of nationally representative values for the non-institutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making 2006;26:391-400.
40. Ariza-Ariza R, Hernandez-Cruz B, Carmona L, Ruiz-Montesinos MD, Ballina J, Navarro-Sarabia F, and the Costs and Quality of Life Rheumatoid Arthritis Study Group. Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol. Arthritis Rheum 2006;55:751-6.
41. Marra CA, Esdaile JM, Guh D, Kopec JA, Brazier JE, Koehler BE, et al. A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Med Care 2004;42:1125-31.
42. Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 2005;60:1571-82.
43. Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford) 2005;44:1169-75.
44. Harrison MJ, Tricker KJ, Davies L, Hassell A, Dawes P, Scott DL, et al. The relationship between social deprivation, disease outcome measures, and response to treatment in patients with stable, long-standing rheumatoid arthritis. J Rheumatol 2005;32:2330-6.
45. Marra CA, Lynd LD, Esdaile JM, Kopec J, Anis AH. The impact of low family income on self-reported health outcomes in patients with rheumatoid arthritis within a publicly funded health-care environment. Rheumatology (Oxford) 2004;43:1390-7.
46. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997;36:551-9.
47. Marra CA, Rashidi AA, Guh D, Kopec JA, Abrahamowicz M, Esdaile JM, et al. Are indirect utility measures reliable and responsive in rheumatoid arthritis patients? Qual Life Res 2005;14:1333-44.
48. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001;28:1842-6.
49. Torrance GW, Tugwell P, Amorosi S, Chartash E, Sengupta N. Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. Rheumatology (Oxford) 2004;43:712-8.
50. Bombardier C, Ware J, Russell IJ, Larson M, Chalmers A, Read JL. Auranofin therapy and quality of life in patients with rheumatoid arthritis: results of a multicenter trial. Am J Med 1986;81:565-78.
51. Ariza-Ariza R, Hernandez-Cruz B, Navarro-Sarabia F. Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis. Arthritis Rheum 2003;49:483-7.
52. Haywood KL, Garratt AM, Dziedzic K, Dawes PT. Generic measures of health-related quality of life in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology (Oxford) 2002;41:1380-7.
53. Van Tubergen A, Boonen A, Landewe R, Rutten-Van Molken M, van der Heijde D, Hidding A, et al. Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2002;47:459-67.
54. Kobelt G, Andlin-Sobocki P, Brophy S, Jonsson L, Calin A, Braun J. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology (Oxford) 2004;43:1158-66.
55. Ostendorf M, van Stel HF, Buskens E, Schrijvers AJ, Marting LN, Verbout AJ, et al. Patient-reported outcome in total hip replacement: a comparison of five instruments of health status. J Bone Joint Surg Br 2004;86:801-8.
56. Patrick DL, Ramsey SD, Spencer AC, Kinne S, Belza B, Topolski TD. Economic evaluation of aquatic exercise for persons with osteoarthritis. Med Care 2001;39:413-24.
57. Feeny D, Wu L, Eng K. Comparing Short Form 6D, standard gamble, and Health Utilities Index Mark 2 and Mark 3 utility scores: results from total hip arthroplasty patients. Qual Life Res 2004;13:1659-70.
58. Fransen M, Edmonds J. Reliability and validity of the EuroQol in patients with osteoarthritis of the knee. Rheumatology (Oxford) 1999;38:807-13.
59. Groessl EJ, Kaplan RM, Cronan TA. Quality of well-being in older people with osteoarthritis. Arthritis Rheum 2003;49:23-8.
60. Cockerill W, Lunt M, Silman AJ, Cooper C, Lips P, Bhalla AK, et al. Health-related quality of life and radiographic vertebral fracture. Osteoporos Int 2004;15:113-9.
61. Adachi JD, Loannidis G, Berger C, Joseph L, Papaioannou A, Pickard L, et al. The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int 2001;12:903-8.
62. Brazier JE, Green C, Kanis JA, and the Committee of Scientific Advisors International Osteoporosis Foundation. A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 2002;13:768-76.
63. Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 2000;15:1384-92.
64. Tosteson AN, Gabriel SE, Kneeland TS, Moncur MM, Manganiello PD, Schiff I, et al. Has the impact of hormone replacement therapy on health-related quality of life been undervalued? J Womens Health Gend Based Med 2000;9:119-30.
65. Dolan P, Roberts J. Modelling valuations for EQ-5D health states: an alternative model using differences in valuations. Med Care 2002;40:442-6.
66. Johnson JA, Luo N, Shaw JW, Kind P, Coons SJ. Valuations of EQ-5D health states: are the United States and United Kingdom different? Med Care 2005;43:221-8.
67. Feeny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status classification systems: Health Utilities Index. Pharmacoeconomics 1995;7:490-502.
68. Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004;13:873-84.
69. Marra CA. Not all "quality-adjusted life years" are equal. J Clin Epidemiol 2007;60:616-24.
70. McGregor M, Caro JJ. QALYs: are they helpful to decision makers? Pharmacoeconomics 2006;24:947-52.
71. Birch S, Gafni A. Information created to evade reality (ICER): things we should not look to for answers. Pharmacoeconomics 2006;24:1121-31.
72. Gafni A, Birch S. Searching for a common currency: critical appraisal of the scientific basis underlying European harmonization of the measurement of health related quality of life (EuroQol). Health Policy 1993;23:219-28.
73. Duru G, Auray JP, Beresniak A, Lamure M, Paine A, Nicoloyannis N. Limitations of the methods used for calculating quality-adjusted life-year values. Pharmacoeconomics 2002;20:463-73.
74. Hewlett S, Cockshott Z, Byron M, Kitchen K, Tipler S, Pope D, et al. Patients' perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum 2005;53:697-702.